Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Holding CHRS?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.31Last Year’s EPS
-$0.71Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 110.24%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth for UDENYCA and LOQTORZI, improved financial performance, and promising pipeline advancements. However, challenges included a supply interruption affecting UDENYCA and a net loss, though financial losses were reduced compared to the previous year.Company Guidance
During the Q3 2024 earnings call for Coherus BioSciences, the company provided guidance on several key metrics. UDENYCA, their leading product, achieved a 100% revenue growth year-over-year, reaching $66 million for the quarter with a 30% increase from Q2 to Q3. UDENYCA retained nearly a 30% market share, holding the #2 position. The company anticipates market growth for UDENYCA to resume in 2025. They addressed a supply chain interruption but reported that production would resume, processing 120,000 units over the next 5 weeks, aiming to restock distribution channels promptly. LOQTORZI, their immuno-oncology agent, saw a 54% increase in sales quarter-over-quarter, with net revenue reaching $5.8 million. Coherus aims to expand LOQTORZI's market presence, targeting a $150 million to $200 million market opportunity. Financially, Coherus reduced their expected R&D and SG&A expenses range to $250 million to $260 million for 2024, reflecting their strategic focus and cost management efforts.UDENYCA Revenue Growth
UDENYCA achieved 100% revenue growth since Q3 2023, reaching $66 million this quarter, with a 30% increase from Q2 to Q3 2024.
LOQTORZI Sales Increase
LOQTORZI sales grew 54% quarter-over-quarter, with net revenue of $5.8 million in Q3 2024.
Improved Financial Performance
Gross profit improved by 20%, and there was a significant reduction in costs, including a 28% decrease in SG&A expenses and a 48% decrease in interest expense.
Pipeline Advancements
Progress in Phase I and II clinical trials for CHS-114 and casdozo, with further data expected in the first half of 2025.
---
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $0.72 | $0.82 | +13.89% |
| Aug 08, 2024 | $1.29 | $1.43 | +10.85% |
| May 09, 2024 | $2.12 | $1.90 | -10.38% |
| Mar 13, 2024 | $2.30 | $2.17 | -5.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.31.
---